Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simon Tiberi1, Ruaridh Buchanan1, José A Caminero2

  • 1Barts Health NHS Trust, Royal London Hospital, Division of Infection, 80 Newark Street, E1 2ES London, United Kingdom.

Presse Medicale (Paris, France : 1983)
|March 4, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Tuberculosis Lung Disease: The Role of Surgical Management.

Thoracic surgery clinics·2026
Same author

Surgery for Active and Drug-Resistant Tuberculosis.

Thoracic surgery clinics·2026
Same author

Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.

Microorganisms·2026
Same author

Update on Tuberculosis Treatment and Drug Regimens.

Cold Spring Harbor perspectives in medicine·2026
Same author

World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Do we need to revise the dose of isoniazid for the treatment of tuberculosis in children?

The European respiratory journal·2026
This summary is machine-generated.

Tuberculosis treatment is evolving with new drugs and shorter regimens for drug-resistant strains. Advances offer hope for patients with limited options, moving closer to tuberculosis elimination.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Tuberculosis (TB) remains a leading infectious cause of death globally.
  • Increasing drug resistance complicates treatment, increasing morbidity, mortality, and costs.
  • The first-line TB regimen, unchanged since the 1970s, faces challenges with pill burden and duration.

Purpose of the Study:

  • To provide an update on novel treatments for both drug-susceptible and drug-resistant tuberculosis.
  • To highlight new drugs in clinical trials and current use.
  • To discuss the implications of new drugs on preventing further resistance.

Main Methods:

  • Review of recent advancements in tuberculosis pharmacotherapy.
  • Analysis of new and repurposed drugs for TB treatment.

Related Experiment Videos

  • Discussion of ongoing clinical trials for novel TB regimens.

    • Main Results:

    • Significant progress has been made in TB treatment in recent years.
    • New WHO-recommended shorter regimens for multidrug-resistant TB are emerging.
    • New drugs like bedaquiline, delamanid, clofazimine, and linezolid offer new treatment possibilities.

    Conclusions:

    • New drugs and regimens provide hope for previously untreatable TB cases.
    • Rational use of these drugs is crucial to prevent the emergence of further resistance.
    • Ongoing research aims to develop universal regimens for all TB cases, advancing towards elimination.